Arcutis Biotherapeutics, Inc.
ARQT Nasdaq
SEC CIK 1787306
Follow Arcutis Biotherapeutics
Weekly email: filings, results
Revenue, last quarter
$143.9M
+45.1% vs same quarter last year
Net income
$8.8M
+18.8% vs same quarter last year
EPS, diluted
$0.06
+0% vs same quarter last year
Operating cash flow
$18.9M
+1177.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $376.1M | −$16.1M |
| FY24 | $196.5M | −$140M |
| FY23 | $59.6M | −$262.1M |
| FY22 | $3.7M | −$311.5M |
| FY21 | $0 | −$206.4M |
| FY20 | $0 | −$135.7M |
| FY19 | - | −$42M |
| FY18 | - | −$19.3M |
| FY17 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 90.2% | −3.3% | −4.3% |
| FY24 | 90.3% | −65.3% | −71.3% |
| FY23 | 91.6% | −404.5% | −439.8% |
| FY22 | 79.5% | −8183% | −8449.8% |
| FY21 | - | - | - |
| FY20 | - | - | - |
| FY19 | - | - | - |
| FY18 | - | - | - |
| FY17 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$6.3M |
| FY24 | −$112.3M |
| FY23 | −$247.5M |
| FY22 | −$258M |
| FY21 | −$175.6M |
| FY20 | −$113.4M |
| FY19 | −$43.1M |
| FY18 | −$14.1M |
| FY17 | - |
- Arcutis Biotherapeutics
- Healthcare median
Show the numbers
| Year | Arcutis Biotherapeutics | Healthcare median |
|---|---|---|
| FY25 | −4.3% | −30.6% |
| FY24 | −71.3% | −47% |
| FY23 | −439.8% | −58% |
| FY22 | −8449.8% | −80.4% |
| FY21 | - | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |